Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.
In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of the 6 patients. In the dosage used, clozapine's usefulness was limited by its propensity to produce sedation, confusion, and increased parkinsonism.
Wolters
E C
EC
Department of Medicine, University Hospital, University of British Columbia, Vancouver, Canada.
Hurwitz
T A
TA
Mak
E
E
Teal
P
P
Peppard
F R
FR
Remick
R
R
Calne
S
S
Calne
D B
DB
D000368:Aged; D000369:Aged, 80 and over; D003024:Clozapine / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology*; D011569:Psychiatric Status Rating Scales; D011605:Psychoses, Substance-Induced / Q000209:etiology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012890:Sleep / Q000187:drug effects
D003984:Dibenzazepines; D015259:Dopamine Agents; D003024:Clozapine